tiprankstipranks
Oric Pharmaceuticals Inc (ORIC)
NASDAQ:ORIC
US Market
ORIC
Oric Pharmaceuticals
RESEARCH TOOLSreports
Want to see ORIC full AI Analyst Report?

Oric Pharmaceuticals (ORIC) Stock Forecast & Price Target

521 Followers
See the Price Targets and Ratings of:

ORIC Analyst Ratings

Strong Buy
11Ratings
Strong Buy
11 Buy
0 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Oric
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ORIC Stock 12 Month Forecast

Average Price Target

$20.89
▲(94.32% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Oric Pharmaceuticals in the last 3 months. The average price target is $20.89 with a high forecast of $25.00 and a low forecast of $15.00. The average price target represents a 94.32% change from the last price of $10.75.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","15":"$15","26":"$26","9.5":"$9.5","20.5":"$20.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.88888888888889,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,9.5,15,20.5,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.77,10.94153846153846,12.113076923076923,13.284615384615385,14.456153846153846,15.627692307692307,16.799230769230768,17.970769230769232,19.142307692307693,20.313846153846153,21.485384615384618,22.65692307692308,23.82846153846154,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.77,10.625299145299145,11.48059829059829,12.335897435897436,13.191196581196582,14.046495726495728,14.901794871794872,15.757094017094017,16.61239316239316,17.46769230769231,18.322991452991452,19.1782905982906,20.033589743589744,{"y":20.88888888888889,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.77,10.172307692307692,10.574615384615385,10.976923076923077,11.37923076923077,11.781538461538462,12.183846153846154,12.586153846153845,12.98846153846154,13.39076923076923,13.793076923076924,14.195384615384615,14.597692307692308,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.57,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.47,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.14,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.12,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.38,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.71,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.16,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.15,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.18,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.16,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.88,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.475,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.77,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$25.00Average Price Target$20.89Lowest Price Target$15.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on ORIC
Corinne Johnson
Goldman Sachs
Goldman Sachs
―
Buy
―
Reiterated
05/15/26
ORIC Pharma: Buy Rating on Rinzimetostat’s Promising Efficacy, Favorable Safety, and 2026 MEVPRO-1 Readout Catalyst
Wedbush Analyst forecast on ORIC
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$17
Buy
58.14%
Upside
Initiated
05/05/26
Oric Pharmaceuticals (ORIC) Initiated with a Buy at Wedbush
Piper Sandler Analyst forecast on ORIC
Kelsey Goodwin
Piper Sandler
Piper Sandler
$22
Buy
104.65%
Upside
Reiterated
05/05/26
Piper Sandler Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)
Wells Fargo Analyst forecast on ORIC
Derek Archila
Wells Fargo
Wells Fargo
$25
Buy
132.56%
Upside
Reiterated
05/05/26
Oric Pharmaceuticals (ORIC) Receives a Buy from Wells Fargo
JonesTrading Analyst forecast on ORIC
Boris Peaker
JonesTrading
JonesTrading
$25
Buy
132.56%
Upside
Reiterated
05/05/26
ORIC Pharmaceuticals: Buy Rating Backed by Advancing Oncology Pipeline, Phase 3 Prostate Cancer Trial and 2026 NSCLC Data Catalysts
H.C. Wainwright Analyst forecast on ORIC
Robert Burns
H.C. Wainwright
H.C. Wainwright
$25
Buy
132.56%
Upside
Reiterated
05/05/26
Analysts Are Bullish on Top Healthcare Stocks: Addus Homecare (ADUS), Vertex Pharmaceuticals (VRTX)
Citi Analyst forecast on ORIC
Yigal Nochomovitz
Citi
Citi
$17→$16
Buy
48.84%
Upside
Assigned
05/05/26
Oric Pharmaceuticals price target lowered to $16 from $17 at CitiOric Pharmaceuticals price target lowered to $16 from $17 at Citi
Oppenheimer Analyst forecast on ORIC
Matthew Biegler
Oppenheimer
Oppenheimer
$15
Buy
39.53%
Upside
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (NASDAQ: ORIC), Fortrea Holdings Inc. (NASDAQ: FTRE) and Edwards Lifesciences (NYSE: EW)
Guggenheim Analyst forecast on ORIC
Bradley Canino
Guggenheim
Guggenheim
$18
Buy
67.44%
Upside
Reiterated
05/04/26
Guggenheim Remains a Buy on Oric Pharmaceuticals (ORIC)
J.P. Morgan Analyst forecast on ORIC
Anupam Rama
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
04/13/26
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD), Oric Pharmaceuticals (NASDAQ: ORIC) and Irhythm Technologies (NASDAQ: IRTC)
Evercore ISI Analyst forecast on ORIC
Cory Kasimov
Evercore ISI
Evercore ISI
$25
Buy
132.56%
Upside
Reiterated
04/01/26
Oric Pharmaceuticals (ORIC) Receives a Buy from Evercore ISI
Roth MKM Analyst forecast on ORIC
Unknown Analyst
Roth MKM
Not Ranked
Roth MKM
$15
Buy
39.53%
Upside
Reiterated
12/08/25
Roth MKM Reaffirms Their Buy Rating on Oric Pharmaceuticals (ORIC)
Wolfe Research Analyst forecast on ORIC
Unknown Analyst
Wolfe Research
Not Ranked
Wolfe Research
―
Hold
―
Initiated
11/17/25
Oric Pharmaceuticals initiated with a Peer Perform at Wolfe ResearchOric Pharmaceuticals initiated with a Peer Perform at Wolfe Research
Ladenburg Thalmann & Co. Analyst forecast on ORIC
Kevin DeGeeter
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
$15
Buy
39.53%
Upside
Reiterated
11/14/25
Oric Pharmaceuticals (ORIC) Gets a Buy from Ladenburg Thalmann & Co.
Cantor Fitzgerald Analyst forecast on ORIC
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
09/26/25
Oric Pharmaceuticals (ORIC) Receives a Buy from Cantor Fitzgerald
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on ORIC
Corinne Johnson
Goldman Sachs
Goldman Sachs
―
Buy
―
Reiterated
05/15/26
ORIC Pharma: Buy Rating on Rinzimetostat’s Promising Efficacy, Favorable Safety, and 2026 MEVPRO-1 Readout Catalyst
Wedbush Analyst forecast on ORIC
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$17
Buy
58.14%
Upside
Initiated
05/05/26
Oric Pharmaceuticals (ORIC) Initiated with a Buy at Wedbush
Piper Sandler Analyst forecast on ORIC
Kelsey Goodwin
Piper Sandler
Piper Sandler
$22
Buy
104.65%
Upside
Reiterated
05/05/26
Piper Sandler Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)
Wells Fargo Analyst forecast on ORIC
Derek Archila
Wells Fargo
Wells Fargo
$25
Buy
132.56%
Upside
Reiterated
05/05/26
Oric Pharmaceuticals (ORIC) Receives a Buy from Wells Fargo
JonesTrading Analyst forecast on ORIC
Boris Peaker
JonesTrading
JonesTrading
$25
Buy
132.56%
Upside
Reiterated
05/05/26
ORIC Pharmaceuticals: Buy Rating Backed by Advancing Oncology Pipeline, Phase 3 Prostate Cancer Trial and 2026 NSCLC Data Catalysts
H.C. Wainwright Analyst forecast on ORIC
Robert Burns
H.C. Wainwright
H.C. Wainwright
$25
Buy
132.56%
Upside
Reiterated
05/05/26
Analysts Are Bullish on Top Healthcare Stocks: Addus Homecare (ADUS), Vertex Pharmaceuticals (VRTX)
Citi Analyst forecast on ORIC
Yigal Nochomovitz
Citi
Citi
$17→$16
Buy
48.84%
Upside
Assigned
05/05/26
Oric Pharmaceuticals price target lowered to $16 from $17 at CitiOric Pharmaceuticals price target lowered to $16 from $17 at Citi
Oppenheimer Analyst forecast on ORIC
Matthew Biegler
Oppenheimer
Oppenheimer
$15
Buy
39.53%
Upside
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (NASDAQ: ORIC), Fortrea Holdings Inc. (NASDAQ: FTRE) and Edwards Lifesciences (NYSE: EW)
Guggenheim Analyst forecast on ORIC
Bradley Canino
Guggenheim
Guggenheim
$18
Buy
67.44%
Upside
Reiterated
05/04/26
Guggenheim Remains a Buy on Oric Pharmaceuticals (ORIC)
J.P. Morgan Analyst forecast on ORIC
Anupam Rama
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
04/13/26
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD), Oric Pharmaceuticals (NASDAQ: ORIC) and Irhythm Technologies (NASDAQ: IRTC)
Evercore ISI Analyst forecast on ORIC
Cory Kasimov
Evercore ISI
Evercore ISI
$25
Buy
132.56%
Upside
Reiterated
04/01/26
Oric Pharmaceuticals (ORIC) Receives a Buy from Evercore ISI
Roth MKM Analyst forecast on ORIC
Unknown Analyst
Roth MKM
Not Ranked
Roth MKM
$15
Buy
39.53%
Upside
Reiterated
12/08/25
Roth MKM Reaffirms Their Buy Rating on Oric Pharmaceuticals (ORIC)
Wolfe Research Analyst forecast on ORIC
Unknown Analyst
Wolfe Research
Not Ranked
Wolfe Research
―
Hold
―
Initiated
11/17/25
Oric Pharmaceuticals initiated with a Peer Perform at Wolfe ResearchOric Pharmaceuticals initiated with a Peer Perform at Wolfe Research
Ladenburg Thalmann & Co. Analyst forecast on ORIC
Kevin DeGeeter
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
$15
Buy
39.53%
Upside
Reiterated
11/14/25
Oric Pharmaceuticals (ORIC) Gets a Buy from Ladenburg Thalmann & Co.
Cantor Fitzgerald Analyst forecast on ORIC
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
09/26/25
Oric Pharmaceuticals (ORIC) Receives a Buy from Cantor Fitzgerald
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Oric Pharmaceuticals

3 Months
Anupam RamaJ.P. Morgan
Success Rate
9/18 ratings generated profit
50%
Average Return
+8.29%
Copying Anupam Rama's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +8.29% per trade.
1 Year
Matthew BieglerOppenheimer
Success Rate
7/15 ratings generated profit
47%
Average Return
+6.68%
Copying Matthew Biegler's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of +6.68% per trade.
2 Years
Anupam RamaJ.P. Morgan
Success Rate
7/18 ratings generated profit
39%
Average Return
+18.16%
Copying Anupam Rama's trades and holding each position for 2 Years would result in 38.89% of your transactions generating a profit, with an average return of +18.16% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ORIC Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
20
18
13
14
17
Buy
7
9
8
9
5
Hold
1
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
28
27
21
23
22
In the current month, ORIC has received 22 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ORIC average Analyst price target in the past 3 months is 20.89.
Each month's total comprises the sum of three months' worth of ratings.

ORIC Financial Forecast

ORIC Earnings Forecast

Next quarter’s earnings estimate for ORIC is -$0.36 with a range of -$0.40 to -$0.30. The previous quarter’s EPS was -$0.34. ORIC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ORIC has Performed in-line its overall industry.
Next quarter’s earnings estimate for ORIC is -$0.36 with a range of -$0.40 to -$0.30. The previous quarter’s EPS was -$0.34. ORIC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ORIC has Performed in-line its overall industry.
No data currently available

ORIC Sales Forecast

Next quarter’s sales forecast for ORIC is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ORIC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ORIC has Performed in-line its overall industry.
Next quarter’s sales forecast for ORIC is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ORIC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ORIC has Performed in-line its overall industry.

ORIC Stock Forecast FAQ

What is ORIC’s average 12-month price target, according to analysts?
Based on analyst ratings, Oric Pharmaceuticals Inc’s 12-month average price target is 20.89.
    What is ORIC’s upside potential, based on the analysts’ average price target?
    Oric Pharmaceuticals Inc has 94.32% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ORIC a Buy, Sell or Hold?
          Oric Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Oric Pharmaceuticals Inc’s price target?
            The average price target for Oric Pharmaceuticals Inc is 20.89. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $25.00 ,the lowest forecast is $15.00. The average price target represents 94.32% Increase from the current price of $10.75.
              What do analysts say about Oric Pharmaceuticals Inc?
              Oric Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of ORIC?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.